67
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Aldehyde dehydrogenase as an alternative to enumeration of total and viable CD34+ cells in autologous hematopoietic progenitor cell transplantation

, , &
Pages 1256-1258 | Received 17 May 2011, Accepted 27 Jun 2011, Published online: 12 Sep 2011
 

Abstract

We validated the correlation of aldehyde dehydrogenase ALDHbr cells with total and viable CD34+ cells in fresh and thawed hematopoietic progenitor cell (HPC) products, and looked for a correlation with time to white blood cell (WBC) and platelet engraftment after autologous transplantation, using simple linear regression analyzes. We found a significant correlation between pre-freeze ALDHbr cell numbers and pre-freeze total CD34+ (P < 0.001), viable CD34+ (P < 0.001) and post-thaw viable CD34+ (P < 0.001) cell numbers. We suggest that ALDHbr may be substituted for CD34+ cell numbers when evaluating HPC. As post-thaw viability testing apparently adds no significant information, we suggest that it may not be necessary. Finally, neither marker correlated with time to engraftment in our patients, supporting previous data suggesting the existence of a threshold dose for timely engraftment around 2.5 × 106 cells/kg.

Conflicts of interest: The authors declare that they have no conflicts of interest relevant to the manuscript.

Source of support: None.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.